MA27716A1 - 4-aminopyrimidine-5-one - Google Patents

4-aminopyrimidine-5-one

Info

Publication number
MA27716A1
MA27716A1 MA28472A MA28472A MA27716A1 MA 27716 A1 MA27716 A1 MA 27716A1 MA 28472 A MA28472 A MA 28472A MA 28472 A MA28472 A MA 28472A MA 27716 A1 MA27716 A1 MA 27716A1
Authority
MA
Morocco
Prior art keywords
compounds
cancer
preparation
treatment
control
Prior art date
Application number
MA28472A
Other languages
English (en)
Inventor
Chu Xin-Jie
Ding Qingjie
Jiang Nan
John Lovey Allen
Anthony Moliterni John
John Guilfoyle Mullin Jr
Thanh Vu Binh
Michael Wovkulich Peter
Joseph Bartkovitz David
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA27716A1 publication Critical patent/MA27716A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention a trait à de nouveaux dérivés de 4-aminopyrimidine-5-one de formule (I), dans laquelle R1 et R2 sont tels que définis dans la description. Ces composés sont inhibiteurs de la kinase dépendante des cyclines, notamment de la kinase 4 dépendante des cyclines (Cdk4). Ces composés et leurs sels et esters pharmaceutiquement acceptables présentent une activité antiproliférative et sont utiles dans le traitement ou le contrôle du cancer, en particulier des tumeurs solides. La présente invention a également trait à des compositions pharmaceutiques contenant de tels composés, leur utilisation pour le traitement et le contrôle du cancer, à leur procédé de préparation et à des intermédiaires utiles dans leur préparation.
MA28472A 2003-02-10 2005-08-30 4-aminopyrimidine-5-one MA27716A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44627303P 2003-02-10 2003-02-10
US51492603P 2003-10-28 2003-10-28

Publications (1)

Publication Number Publication Date
MA27716A1 true MA27716A1 (fr) 2006-01-02

Family

ID=32853425

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28472A MA27716A1 (fr) 2003-02-10 2005-08-30 4-aminopyrimidine-5-one

Country Status (22)

Country Link
US (2) US7157455B2 (fr)
EP (1) EP1628619A2 (fr)
JP (1) JP2006523183A (fr)
KR (1) KR100717099B1 (fr)
AR (1) AR043693A1 (fr)
AU (1) AU2004210408A1 (fr)
BR (1) BRPI0407381A (fr)
CA (1) CA2512915A1 (fr)
CL (1) CL2004000226A1 (fr)
EA (1) EA009412B1 (fr)
EC (1) ECSP055958A (fr)
HR (1) HRP20050689A2 (fr)
IL (1) IL169626A0 (fr)
MA (1) MA27716A1 (fr)
MX (1) MXPA05008333A (fr)
MY (1) MY137555A (fr)
NO (1) NO20053410L (fr)
PL (1) PL382309A1 (fr)
RS (1) RS20050610A (fr)
TN (1) TNSN05188A1 (fr)
TW (1) TWI293881B (fr)
WO (1) WO2004069139A2 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7211576B2 (en) * 2004-04-20 2007-05-01 Hoffmann-La Roche Inc. Diaminothiazoles
US7405220B2 (en) 2004-06-09 2008-07-29 Hoffmann-La Roche Inc. Pyrazolopyrimidines
EP1726953B1 (fr) * 2005-05-25 2008-08-20 F. Hoffmann-La Roche Ag Biomarqueur pour surveiller la réponse des inhibiteurs CDK dans la clinique
US7705009B2 (en) * 2005-11-22 2010-04-27 Hoffman-La Roche Inc. 4-aminopyrimidine-5-thione derivatives
KR20100129331A (ko) 2005-12-01 2010-12-08 에프. 호프만-라 로슈 아게 항암제로서 사용하기 위한 ｐ53 및 ｍｄｍ2 단백질 간 상호작용의 저해제로서의 2,4,5-트리페닐 이미다졸린 유도체
WO2007113005A2 (fr) * 2006-04-03 2007-10-11 European Molecular Biology Laboratory (Embl) Inhibiteurs de la kinase aurora
WO2010019967A1 (fr) * 2008-08-15 2010-02-18 Georgetown University Inhibiteurs de cdk fluorescents pour le traitement du cancer
AR081626A1 (es) 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
EP2560488B1 (fr) 2010-04-23 2015-10-28 Cytokinetics, Inc. Aminopyridines et aminotriazines, leurs compositions et leurs procédés d'utilisation
AR081331A1 (es) 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
BR112016030787B1 (pt) * 2014-07-01 2022-12-20 Takeda Pharmaceutical Company Limited Entidade química, composição farmacêutica e seu uso
KR20220016909A (ko) * 2019-06-06 2022-02-10 베이징 타이드 파마슈티컬 코퍼레이션 리미티드 P2x3 및/또는 p2x2/3 수용체 길항제, 이를 함유하는 약학적 조성물 및 이의 용도
US20250009745A1 (en) * 2021-02-05 2025-01-09 Shanghai Qilu Pharmaceutical Research And Development Centre Ltd. Cdk inhibitor
KR20250078953A (ko) * 2022-09-22 2025-06-04 조인트 스탁 컴퍼니 "바이오케드" 사이클린-의존성 키나아제 7 억제제

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9012592D0 (en) 1990-06-06 1990-07-25 Smithkline Beecham Intercredit Compounds
WO1998033798A2 (fr) * 1997-02-05 1998-08-06 Warner Lambert Company Pyrido[2,3d]pyrimidines et 4-aminopyrimidines en tant qu'inhibiteurs de la proliferation cellulaire
PL342447A1 (en) 1997-10-27 2001-06-04 Agouron Pharma Substituted 4-amino thiazol-2-yl compounds as inhibitors of cyclin-dependent kinases
US6262096B1 (en) 1997-11-12 2001-07-17 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
BR9908004A (pt) 1998-02-17 2001-12-18 Tularik Inc Composto, composição e método para prevençãoou supressão de uma infecção viral
ATE342892T1 (de) 1998-08-29 2006-11-15 Astrazeneca Ab Pyrimidine verbindungen
GB9828511D0 (en) 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
NZ516872A (en) 1999-09-15 2003-10-31 Warner Lambert Co Pteridinones as kinase inhibitors
BR0015718A (pt) 1999-11-22 2002-07-23 Warner Lambert Co Quinazolinas e seu uso para inibição de enzimas de cinase dependente de ciclina
HUP0204141A3 (en) * 2000-01-25 2005-03-29 Warner Lambert Co Pyrido[2,3d]pyrimidine-2,7-diamine inhibitors, pharmaceutical compositions containing them and their use
IL150742A0 (en) * 2000-01-27 2003-02-12 Warner Lambert Co Pyridopyrimidinone derivatives for the treatment of neurodegenerative disease
GB0004888D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004886D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004887D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
BR0110302A (pt) 2000-04-18 2003-01-14 Agouron Pharma Compostos de pirazol para inibição de proteìnas cinase, sal e pró-droga farmaceuticamente aceitável, metabólito farmaceuticamente ativo ou sal farmaceuticamente aceitável de metabólito, composição farmacêutica, método de tratamento de condição doentia em mamìferos mediada pela atividade de proteìna cinase, método de modulação ou inibição da atividade de um receptor de proteìna cinase
AP2003002762A0 (en) * 2000-09-15 2003-03-31 Vertex Pharma Pyrazole compounds useful as protein kinase inhibitors
AU2002255452B2 (en) * 2000-12-21 2006-06-08 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
MXPA03010810A (es) 2001-05-29 2004-03-22 Schering Ag Pirimidinas inhibidoras de cdk, su obtencion y su uso como medicamentos.
US7288547B2 (en) 2002-03-11 2007-10-30 Schering Ag CDK-inhibitory 2-heteroaryl-pyrimidines, their production and use as pharmaceutical agents
BR0316680A (pt) 2002-11-28 2005-10-18 Schering Ag Pirimidinas inibidoras de chk, pdk e akt, sua produção e uso como agentes farmacêuticos
JP4828405B2 (ja) * 2003-02-10 2011-11-30 バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト 呼吸器官の細菌性疾患の処置
CA2515095A1 (fr) 2003-02-10 2004-08-19 Pfizer Inc. Schema posologique pour nelfinavir
DE10349423A1 (de) 2003-10-16 2005-06-16 Schering Ag Sulfoximinsubstituierte Parimidine als CDK- und/oder VEGF-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel

Also Published As

Publication number Publication date
ECSP055958A (es) 2006-01-16
KR20050099544A (ko) 2005-10-13
US7615634B2 (en) 2009-11-10
US20060229330A1 (en) 2006-10-12
EA009412B1 (ru) 2007-12-28
EA200501233A1 (ru) 2006-04-28
BRPI0407381A (pt) 2006-02-07
CA2512915A1 (fr) 2004-08-19
WO2004069139A2 (fr) 2004-08-19
AU2004210408A1 (en) 2004-08-19
KR100717099B1 (ko) 2007-05-10
US20040162303A1 (en) 2004-08-19
MY137555A (en) 2009-02-27
WO2004069139A3 (fr) 2007-04-26
TWI293881B (en) 2008-03-01
JP2006523183A (ja) 2006-10-12
US7157455B2 (en) 2007-01-02
AR043693A1 (es) 2005-08-10
IL169626A0 (en) 2007-07-04
EP1628619A2 (fr) 2006-03-01
RS20050610A (sr) 2007-12-31
MXPA05008333A (es) 2005-09-30
NO20053410L (no) 2005-09-08
PL382309A1 (pl) 2007-08-20
CL2004000226A1 (es) 2005-01-14
TNSN05188A1 (en) 2007-06-11
HRP20050689A2 (hr) 2006-08-31
TW200423940A (en) 2004-11-16

Similar Documents

Publication Publication Date Title
MA27568A1 (fr) Derives de pyrrolopyrimidine
TNSN04156A1 (fr) Pyridinones substituees servant de modulateurs de la map-kinase p38
MA28747B1 (fr) Dérivés de pyridine
TNSN05250A1 (fr) Pyrimidinones substituees
TNSN04246A1 (fr) Derives d'heteroarylamides benzocondenses de thienopyridines utiles comme agents therapeutiques, compositions pharmaceutiques les contenant et methodes pour leur utilisation
MA27389A1 (fr) Derives de benzimidazole nouveaux utiles comme agents antiproliferatifs.
MA29926B1 (fr) Derives de pyrazine
MA26727A1 (fr) Derives nouveaux de pyrimidine inhibiteurs de sorbitol deshydrogenase, leur procede de preparation et compositions pharmaceutiques les contenant
MA27716A1 (fr) 4-aminopyrimidine-5-one
MA27774A1 (fr) Inhibiteurs de phosphatidylinositol 3-kinase
TNSN05298A1 (fr) Derives de pyrazolo-quinazoline, procede pour leur preparation et leur utilisation comme inhibiteurs de kinases
MA26733A1 (fr) Derives d'isothiazole nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
MA27775A1 (fr) Composes organiques
MA30075B1 (fr) Derives de pyrimidine pour le traitement d'une croissance cellulaire anormale
RU2203274C2 (ru) Спироциклические ингибиторы металлопротеаз
MA56883B1 (fr) Dérivés de 2-hydroxycycloalcane-1-carbamoyle
TNSN05073A1 (fr) Quinazolinones spirocondensees nouvelles et leur utilisation comme inhibiteurs de phosphodiesterase
MA30142B1 (fr) Agonistes du recepteur de neuropeptide-2
MA26956A1 (fr) Pyrimidine-2,4,6,triones inhibitrices de metalloproteinases.
TN2009000450A1 (fr) Derives de pyridine
TNSN08445A1 (fr) Derives de triazolopyrazine utiles comme agent anticancereux
MA28064A1 (fr) Dérivés de pyrrolo [3,4-c] pyrazole actifs comme inhibiteurs de kinases
EP1689713A4 (fr) Inhibiteurs de benzylether et benzylamino de beta-secretase pour traiter la maladie d'alzheimer
TNSN06439A1 (fr) Derives de 2-carbamide -4-phenylthiazole, leur preparation et leur application en therapeutique
MA31142B1 (fr) Derives heteroaryles de pyrrolidinyl et piperdinyl cetones.